The DOI matches its Crossref record.
Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia
Open accessAbstract
Purpose: Lintuzumab (HuM195) is an unconjugated humanized murine monoclonal antibody directed against the cell surface myelomonocytic differentiation antigen CD33. In this study, the efficacy of lintuzumab in combination with induction chemotherapy was compared with chemotherapy alone in adults with first relapsed or primary refractory acute myeloid leukemia (AML). Patients and Methods: Patients with relapsed or primary resistant AML (duration of first response, zero to 12 months) were randomly assigned to receive either mitoxantrone 8 mg/m 2, etoposide 80 mg/m 2, and cytarabine 1 g/m 2 daily for 6 days (MEC) in combination with lintuzumab 12 mg/m 2, or MEC alone. Overall response, defined as the rate of complete remission (CR) and CR with incomplete platelet recovery (CRp), was the primary end point of the study, with additional analyses of survival time and toxicity. Results: A total of 191 patients were randomly assigned from November 1999 to April 2001. The percent CR plus CRp with MEC plus lintuzumab was 36% v 28% in patients treated with MEC alone (P = .28). The overall median survival was 156 days and was not different in the two arms of the study. Apart from mild antibody infusion–related toxicities (fever, chills, and hypotension), no differences in chemotherapy-related adverse effects, including hepatic and cardiac dysfunction, were observed with the addition of lintuzumab to induction chemotherapy. Conclusion: The addition of lintuzumab to salvage induction chemotherapy was safe, but did not result in a statistically significant improvement in response rate or survival in patients with refractory/relapsed AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A. E., Yin, J., Craddock, C. F., Dufva, I. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2964 · Cited by 409
Meraviglia, S., Eberl, M., Vermijlen, D., Todaro, M., Buccheri, S., Cicero, G., La Mendola, C., Guggino, G., D'Asaro, M., Orlando, V, et al. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04167.x · Cited by 295
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Efficient Killing of Human Colon Cancer Stem Cells by γδ T Lymphocytes
Todaro, M., D'Asaro, M., Caccamo, N., Iovino, F., Francipane, M. G., Meraviglia, S., Orlando, V., La Mendola, C., Gulotta, G., Salerno, A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804288 · Cited by 280
Metadata
- Authors
- Feldman, E. J., Brandwein, J., Stone, R., Kalaycio, M., Moore, J., O'Connor, J., Wedel, N., Roboz, G. J., Miller, C., Chopra, R., Jurcic, J. C., Brown, R., Ehmann, W. C., Schulman, P., Frankel, S. R., De Angelo, D., & Scheinberg, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-06-20
- Volume
- 23
- Issue
- 18
- Pages
- 4110-4116
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163123363
- Cited by
- 249
- References
- 0
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1200/jco.2005.09.133
- The paper
- Feldman, E. J., Brandwein, J., Stone, R., Kalaycio, M., Moore, J., O'Connor, J., Wedel, N., Roboz, G. J., Miller, C., Chopra, R., Jurcic, J. C., Brown, R., Ehmann, W. C., Schulman, P., Frankel, S. R., De Angelo, D., & Scheinberg, D. (2005). Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.09.133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.